KILITCH share price, P/E, ROE & financials

On 6 Nov 2026, Kilitch Drugs (India) was priced at ₹195.25, or 22.2× trailing earnings, against an industry P/E of 28.7×, and the shares are 27% below their 52-week high. Its ROCE of 13% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 19% and 42% a year over 3 years. Debt is 0.32× equity. It is a small-cap company with a market cap of ₹683 Cr, ranked 79th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 7.2% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹206.55
Day high: ₹208.58
Day low: ₹193.03
Prev. close: ₹208.47
Volume: 59.8K

Health check

3 good · 1 fair · 2 to check

ReturnsBehind
+7.2% over a year, better than 1 of 7 peers.
Price tagCheaper
P/E 22.2 vs industry 28.7.
GrowthStrong
Sales +19.2%, profit +42.4% a year over 3 years.
ProfitabilityAverage
ROCE 13.2% vs peer median 17.9%.
Balance sheetStretched
Debt 0.32× equity, interest covered 8.0×, Piotroski 1 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹683 Cr, #79 of 154 in its industry by size.

Defensive

Beta 0.34 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹237 Cr · profit ₹30 Cr

Market cap: ₹683 Cr; Small cap
P/E: 22.2; Industry 28.7
Price to book: 2.44; Peers 4.99
Dividend yield: 0.00%
ROE: 12.5%; Peers 14.7%
ROCE: 13.2%; Peers 17.9%
Debt to equity: 0.32; Debt ₹89 Cr
EPS (TTM): ₹8.80; Face value ₹10
OPM (TTM): 15.3%; Net margin 12.7%
Sales growth: +4.0%; Latest quarter vs a year ago
Profit growth: −3.7%; Latest quarter vs a year ago
Price to sales: 2.88; EV/EBITDA 19.2

Strengths and risks

Nothing stands out either way in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic,…

Headquarters: Mumbai
Employees: 236
Sector: Healthcare
ISIN: INE729D01010
Website: kilitch.com

Price range

52 weeks

₹117.25₹267.90

Today

₹193.03₹208.58

Avg volume (3M): 58.6K
1-year return: plus 7.2%
From 52-week high: minus 27.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
KILITCHKilitch Drugs (India)	195.25	minus 6.34%	683	22.2	2.44	13.2%	12.5%	4.1%	19.2%	42.4%	0.00%	plus 7.2%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
43.1	48.9	53.8	89.6	44.9
39.9	43.9	47.7	67.5	41.9
3.3	5	6.2	22.1	2.9
7.6%	10.3%	11.4%	24.7%	6.5%
2.6	6.7	1.5	0.5	2.9
1.5	1.4	1.1	1.4	0.9
0.8	0.9	0.9	1	1.1
3.4	9.4	5.6	20.2	3.9
34.4%	14.5%	22.9%	26.4%	49.1%
3	8.2	4.4	14.5	2.9
0.94	2.48	1.25	4.24	0.83

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +19.2%
Profit CAGR 3Y: +42.4%
EPS CAGR 3Y: +39.5%
ROE: 12.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
139	154	197	235
–	+10.6%	+28.4%	+19.3%
121	129	165	198
17.9	24.4	31.7	37.8
12.9%	15.9%	16.1%	16.1%
1.8	2.8	6.9	6.4
4.9	5.9	5	5.6
3.6	3.3	3.1	3.6
0.8	1.4	4	3.6
12	19.4	34.5	38.7
31.1%	29.9%	27.7%	23.7%
10.4	14.6	26.7	30.2
–	+39.8%	+82.9%	+13.0%
3.28	4.49	8.12	8.91

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
15.6	16.1	16.1	35
136	160	186	245
22.2	31.6	49.4	88.7
45.7	32.1	61	89.4
220	240	313	458
47.4	48.1	92.8	189
3.6	6	47.3	140
1.4	1.6	1.8	1.6
59.1	69	59.3	68.7
108	115	112	58.7
220	240	313	458

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2.6	−1.5	17.5	24
7.9	−8.2	−39.9	−100
−0.7	8.8	13.2	82.5
9.8	−0.9	−9.2	6
−3.8	−6.5	−46.9	−99.5
−1.2	−8	−29.3	−75.5

Shareholding pattern

Source: NSE filings

63.8%

promoters

Promoters63.77%
Public36.23%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	63.77%	36.23%	0.00
30 Jun 2026	63.77%	36.23%	0.00
31 Mar 2026	63.77%	36.23%	0.00
31 Dec 2025	63.77%	36.23%	0.00
30 Sep 2025	63.77%	36.23%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you